Sucampo has acquired the Lundbeck and Pfizer-backed rare diseases treatment developer for $200m in stock and cash, less than a year after it closed a $42m series A round.
Vtesse, a US-based rare disease therapy developer backed by pharmaceutical firms Pfizer and Lundbeck, was acquired on Monday by biopharmaceutical company Sucampo Pharmaceuticals for $200m.
The transaction consisted of $170m in cash and nearly 2.8 million shares of Sucampo class A common stock.
Vtesse is developing treatments for rare, life-threatening conditions. The company, a spinout of orphan drug accelerator Cydan Development, is undertaking clinical trials for its lead candidate VTS-270, a therapy for the genetic disease Niemann-Pick Type C1.
The…
